Southport cannabis factory features in Canadian company’s global expansion

ASX-listed Epsilon Healthcare and Canadian company Valens have announced a partnership that will see the Australian company provide access to its cannabis manufacturing facility.

Epsilon (formerly THC Group) runs a TGA and EU Good Manufacturing Practice-accredited facility in Southport, Queensland, the southern hemisphere’s largest cannabis extraction site.

Under the partnership, products will be distributed in Australia and New Zealand through Valens’ local distribution partner, Cannvalate, as well as providing Valens the capacity to deliver products to Latin America, Europe, UK and Asia-Pacific.

According to a statement, it will also see Valens “fund all operational and capital expenditure of the Southport Facility in return for preferential access for up to 85 percent of the operational capacity of the Southport Facility over the next five years, with an option to extend this arrangement for an additional six years.”

“We are excited to be working with Valens during such a flourishing time in their corporate trajectory,” said Epsilon CEO Jarrod White.

“Valens also shows a promising production throughput to scale up our GMP manufacturing capability. We look forward to furthering our partnership with Valens in the coming months as we accelerate the commercial production output from Epsilon’s wholly owned facility.”

THC Group rebranded as Epsilon Healthcare in February. 

Its wholly owned subsidiary, THC Pharma operates the 10,000 square foot extraction facility, which “consists of its own QC lab and grade D cleanroom space for the manufacture of oral dose format products.” 

The factory officially opened in August 2019.

Subscribe to our free @AuManufacturing newsletter here.